Evidence map›Paper›PMID 40807274›Full record

ArticleMolecules (Basel, Switzerland)2025

Targeting RARγ Decreases Immunosuppressive Macrophage Polarization and Reduces Tumor Growth.

Jihyeon Park, Jisun Oh, Sang-Hyun Min, Ji Hoon Yu, Jong-Sup Bae, Hui-Jeon Jeon

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jihyeon ParkCollege of Pharmacy, Kyungpook National University, Daegu 41566, Republic of Korea.
Jisun OhNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI hub), Daegu 41061, Republic of Korea.
Sang-Hyun MinDepartment of Innovative Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Republic of Korea.
Ji Hoon YuNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI hub), Daegu 41061, Republic of Korea.
Jong-Sup BaeCollege of Pharmacy, Kyungpook National University, Daegu 41566, Republic of Korea.ORCID 0000-0002-5756-9367
Hui-Jeon JeonNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI hub), Daegu 41061, Republic of Korea.

Funding

National Research Foundation of Korea (NRF) grants funded by the Ministry of Science and ICT, Republic of Korea NRF-2019R1F1A1057906, NRF-2022M3A9J3073020 to H.-J.J. and NRF-2022R1F1A1073646 to J.O.
6 · The paper itself

Abstract

Tumor-associated macrophages (TAMs) play a critical role in the tumor microenvironment (TME), interacting with cancer cells and other components to promote tumor growth. Given the influence of TAMs on tumor progression and resistance to therapy, regulating the activity of these macrophages is crucial for improving cancer treatment outcomes. TAMs often exhibit immunosuppressive phenotypes (commonly referred to as M2-like macrophages), which suppress immune responses and contribute to drug resistance. Therefore, inhibiting immunosuppressive polarization offers a promising strategy to impede tumor growth. This study revealed retinoic acid receptor gamma (RARγ), a nuclear receptor, as a key regulator of immunosuppressive polarization in THP-1 macrophages. Indeed, the inhibition of RARγ, either by a small molecule or gene silencing, significantly reduced the expression of immunosuppressive macrophage markers. In a three-dimensional tumor spheroid model, immunosuppressive macrophages enhanced the proliferation of HCT116 colorectal cancer cells, which was significantly hindered by RARγ inhibition. These findings suggest that targeting RARγ reprograms immunosuppressive macrophages and mitigates the tumor-promoting effects of TAMs, highlighting RARγ as a promising therapeutic target for developing novel anti-cancer strategies.

Indexed as

MacrophagesNeoplasmsReceptors, Retinoic AcidTumor-Associated MacrophagesCell Line, TumorCell ProliferationHCT116 CellsHumansRetinoic Acid Receptor gammaTHP-1 CellsTumor MicroenvironmentReceptors, Retinoic AcidRetinoic Acid Receptor gammaM2 polarizationretinoic acid receptor gammatherapeutic targettumor-associated macrophagestumor microenvironment

Identifiers

PMID40807274
PMCPMC12348448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.